'Double‐Hit' cytogenetic status may not be predicted by baseline clinicopathological characteristics and is highly associated with overall survival in B cell lymphoma patients. (25th April 2014)

• Record Type: Journal Article
• Authors: Landsburg, Daniel J.; Nasta, Sunita D.; Svoboda, Jakub; Morrissette, Jennifer J. D.; Schuster, Stephen J.
• Is Part Of: British journal of haematology. Volume 166:Number 3(2014:Aug.)
• Page Start: 369
• Page End: 374
• Publication Date: 2014-04-25
• Subjects: Hematology -- Periodicals; Blood -- Diseases -- Periodicals; 616.15
• DOI: 10.1111/bjh.12901
• Languages: English
• ISSNs: 0007-1048

Abstract

<abstract abstract-type="main" id="bjh12901-abs-0001"> <title>Summary</title> <p>'Double‐Hit' (DH) B cell non‐Hodgkin lymphomas are characterized by the presence of a <italic>MYC</italic> rearrangement and additional rearrangement(s) most commonly involving <italic>BCL2</italic> and/or <italic>BCL6</italic>. Patients with DH lymphomas are unlikely to achieve long‐term survival when treated with standard immunochemotherapy alone. DH gene rearrangements can be identified through metaphase karyotyping or more sensitive fluorescence <italic>in situ</italic> hybridization (FISH), although the latter is not routinely performed. We report 53 cases of B cell lymphoma that underwent diagnostic metaphase karyotying or FISH for <italic>MYC</italic> rearrangements. DH lymphoma was detected in 17 cases. No baseline factor, including age, serum lactate dehydrogenase, stage, International Prognostic Index or histology predicted for DH status. The median overall survival was significantly shorter for DH compared to non‐DH lymphoma patients (8·2 vs. 56·8 months, <italic>P</italic> < 0·001). DH status retained the most statistically significant association with overall survival on multivariate Cox regression analysis. DH status could not be inferred by baseline disease‐ or patient‐related characteristics and was most predictive of overall survival in this cohort of B cell lymphoma patients. These findings support the practice of routine performance of FISH for DH gene rearrangements on B cell lymphoma specimens in order to effectively identify DH patients who may benefit from risk‐adapted therapy.</p> </abstract>